Evidence map›Paper›PMID 41476540›Full record

ArticleACS omega2025

Design and Preclinical Evaluation of a

Yuchun Zhu, Lian Wang, Qingyan Tang, Jing Wang, Xiaoyi Zhang, Shengming Deng, Yi Yang

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuchun ZhuDepartment of Nuclear Medicine, Kunshan First People's Hospital, Kunshan 215399, China.ORCID https://orcid.org/0009-0004-9518-3336
Lian WangDepartment of Oncology, Xuyi People's Hospital, Huaian 211799, China.
Qingyan TangDepartment of Radiology, Kunshan Jinxi People's Hospital, Kunshan 215324, China.
Jing WangDepartment of Nuclear Medicine, Kunshan First People's Hospital, Kunshan 215399, China.
Xiaoyi ZhangDepartment of Nuclear Medicine, Changshu No. 2 People's Hospital, Changshu 215501, China.
Shengming DengDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Yi YangNuclear Medicine Laboratory of Mianyang Central Hospital, Mianyang 621099, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transferrin Receptor 1 (TfR1/CD71) is frequently overexpressed in colorectal cancer (CRC) and is associated with poor clinical outcomes, making it a compelling target for molecular imaging. However, conventional immunohistochemical (IHC) assessment is limited by spatial heterogeneity. To address this, we developed

Identifiers

PMID41476540
PMCPMC12750270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.